Ovid Therapeutics
OVID
130 hedge funds and large institutions have $396M invested in Ovid Therapeutics in 2026 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 33 increasing their positions, 27 reducing their positions, and 18 closing their positions.
295% more capital inflows, than outflows
Capital inflows: $184M | Capital outflows: $46.6M
156% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 18
118% more call options, than puts
Call options by funds: $547K | Put options by funds: $251K
26% more funds holding
Funds holding: 103 → 130 (+27)
22% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 27
0.91% less ownership
Funds ownership: 79.67% → 78.76% (-0.91%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$24M |
| 2 |
State Street
Boston,
Massachusetts
|
+$19M |
| 3 |
Braidwell
Stamford,
Connecticut
|
+$15.3M |
| 4 |
ADAR1 Capital Management
Austin,
Texas
|
+$7.41M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$7.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
-$9.04M |
| 2 |
ABG
Ally Bridge Group
New York
|
-$5.66M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.84M |
| 4 |
Blue Owl Capital Holdings
New York
|
-$4.23M |
| 5 |
Millennium Management
New York
|
-$3.78M |
OVID Hedge Fund Activity: Q2 2026 in Review
130 of the 8,358 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q2 2026, worth a combined $396M — up 70% from $233M a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new OVID positions and 18 closed out — a net gain of 28 holders — while 33 added to existing stakes and 27 trimmed.
The largest buyer was BlackRock, adding an estimated $24M. The largest seller was Saturn V Capital Management, cutting an estimated $9.04M.
- 130 institutional investors held Ovid Therapeutics (OVID) as of Q2 2026, up from 103 in Q1 2026.
- Funds reported $396M of Ovid Therapeutics stock for Q2 2026, up 70% quarter-over-quarter.
- 46 funds opened new Ovid Therapeutics positions in Q2 2026 and 18 closed out, a net change of +28 holders.
- The largest Ovid Therapeutics buyer in Q2 2026 was BlackRock, an estimated $24M added.
- The largest Ovid Therapeutics seller in Q2 2026 was Saturn V Capital Management, an estimated $9.04M sold.
Based on aggregated 13F filings for Q2 2026.